<DOC>
	<DOCNO>NCT00003352</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy consist doxorubicin , cyclophosphamide , docetaxel treat woman stage IIIB stage IV breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Stage IIIB Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall response rate doxorubicin , docetaxel , cyclophosphamide ( ATC ) woman metastatic locally advanced breast cancer . II . Determine survival , time first response , time progression , duration response patient . III . Evaluate feasibility administer ATC least 4 course . IV . Evaluate toxicity profile ATC effect cardiac function . OUTLINE : Patients receive intravenous doxorubicin 15 minute day 0 , follow intravenous cyclophosphamide 30 minute . An hour end doxorubicin infusion , intravenous docetaxel administer 1 hour . Patients receive course every 21 day disease progression unacceptable toxic effect observe . When maximum dose doxorubicin reach , treatment continue docetaxel cyclophosphamide . Patients locally advance breast cancer receive chemotherapy least 2 course document response . Patients follow every 6 week . PROJECTED ACCRUAL : Approximately 89 patient accrue study within 14 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic ( stage IV ) locally advanced ( stage IIIB ) adenocarcinoma breast . Bidimensionally measurable disease . No active central nervous system ( CNS ) metastasis . Brain metastasis must control least 3 month sit measurable disease . No carcinomatous meningitis . No lymphangitic lung metastasis site metastatic disease . Hormone receptor status : Any estrogen progesterone receptor status . PATIENT CHARACTERISTICS : Age : 18 . Sex : Female . Menopausal status : Not specify . Performance status : Eastern Cooperative Oncology Group ( ECOG ) score range 02 . Life expectancy : At least 6 month . Hematopoietic : Absolute neutrophil count least 2,000/mm3 . Platelet count least 100,000/mm3 . Hepatic : serum glutamic oxaloacetic transaminase ( SGOT ) and/or serum glutamic pyruvic transaminase ( SGPT ) great 2.5 time upper limit normal ( ULN ) . Alkaline phosphatase great 5 time ULN . Bilirubin great ULN . No SGOT and/or SGPT great 1.5 time ULN concomitant alkaline phosphatase great 2.5 time ULN . Renal : Calcium great 1.2 time ULN . Creatinine great 1.5 time ULN . Cardiovascular : leave ventricular ejection fraction ( LVEF ) least institutional low limit normal multiple gated acquisition scan ( MUGA ) echocardiogram . No myocardial infarction within 6 month . No angina pectoris require antianginal medication . No history congestive heart failure . No cardiac arrhythmia require medication . No vascular disease document cardiac function compromise No uncontrolled hypertension ( diastolic great 100 mm Hg ) . Other : Not pregnant nursing . Fertile patient must use effective barrier contraception . No diabetic fast blood sugar great 200 mg/dL . No peripheral neuropathy great grade 1 . No psychosis addictive disorder . No known hypersensitivity E. coliderived drug . PRIOR CONCURRENT THERAPY : Chemotherapy : No prior chemotherapy metastatic breast cancer nonbreast cancer . At least 12 month since nontaxane contain adjuvant chemotherapy primary tumor ( patient metastatic disease ) . Prior adjuvant chemotherapy anthracycline contain regimen allow ( provide total doxorubicin dose exceed 240 mg/m2 ) . Endocrine therapy : At least 4 week since adjuvant hormone hormone therapy metastatic disease ( least 2 week rapidly progressive disease ) . No concurrent hormonal birth control . Radiotherapy : At least 4 week since prior radiotherapy . Prior breast radiotherapy follow lumpectomy allow . No radiotherapy great 30 % bone marrow . No prior leave chest wall radiotherapy anthracycline contain adjuvant chemotherapy . Surgery : Not specify .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>